December 2, 2025 09:00 AM EST
Updated December 4, 04:25 AM
PharmaIn Focus
As approval date looms, Cytokinetics gears up for David-and-Goliath battle with Bristol Myers
Elizabeth Cairns
Senior biopharma journalist
It has taken nearly 30 years, but Cytokinetics is on the cusp of its first-ever approval.
Wall Street regards aficamten — a once-daily pill for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER